ZEPP — Zepp Health Corporation

Summary of Zepp Health Corporation Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 Revenue: $85.2 million, up 43% year-over-year, meeting the upper end of guidance.
• Full Year Revenue: $259 million, representing a 41.8% increase from $183 million in 2024.
• Amazfit Product Sales: Grew 45.4% year-over-year in Q4, with a gross margin of 40.4%, a record high.
• Adjusted Net Loss: $6.4 million in Q4, improved from a loss of $22.5 million in Q4 2024; full year adjusted net loss was $31.5 million, down from $56.7 million in 2024.
• Cash Position: Cash and cash equivalents increased to $113 million from $103 million in Q3 2025.

2. Strategic Updates and Business Highlights:

• Transitioning from a traditional hardware company to a hybrid training platform integrating hardware, software, and data capabilities.
• Launched new products including the Amazfit Active MAX and T-Rex Ultra 2, targeting both entry-level and premium segments.
• Strengthening brand credibility through partnerships with elite athletes and collaborations with HYROX, enhancing visibility and engagement.
• Continued investment in the Zepp OS ecosystem to improve user engagement and retention.

3. Forward Guidance and Outlook:

• Q1 2026 Revenue Guidance: Expected between $50 million to $55 million, indicating a year-over-year growth of 30% to 43%.
• Confidence in sustained demand beyond seasonal trends, with a focus on premium product expansion and margin improvement.

4. Bad News, Challenges, or Points of Concern:

• Operating expenses increased by $8 million year-over-year, primarily due to strategic investments and provisions for potential bad debts.
• The company faces macroeconomic challenges, including rising memory chip costs and inflationary pressures, although they believe their pricing strategy can mitigate these impacts.
• Despite improvements, there are concerns regarding the sustainability of operating losses and the need for ongoing cost management.

5. Notable Q&A Insights:

• The company plans to launch a similar or slightly higher number of new products in 2026 compared to 2025.
• Management expressed confidence in navigating currency fluctuations, noting minimal exposure to U.S. dollar strength.
• The Adventure series is increasingly contributing to overall sales and average selling price (ASP) improvements.
• Challenges in meeting demand for the Helio Strap were acknowledged, with plans to enhance manufacturing capabilities in 2026.

Overall, Zepp Health Corporation reported strong growth in Q4 2025, driven by a successful product strategy and brand positioning, while also addressing challenges related to operating expenses and macroeconomic factors. The outlook for 2026 remains positive with expectations for continued revenue growth and margin expansion.